Compare IHRT & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IHRT | RLMD |
|---|---|---|
| Founded | 1974 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 300.3M | 348.8M |
| IPO Year | 2019 | 2012 |
| Metric | IHRT | RLMD |
|---|---|---|
| Price | $1.80 | $3.25 |
| Analyst Decision | Sell | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $3.63 | ★ $10.75 |
| AVG Volume (30 Days) | 637.3K | ★ 1.4M |
| Earning Date | 11-09-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 54.19 | 45.28 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,864,991,000.00 | $13,070.00 |
| Revenue This Year | $7.20 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | 0.27 | ★ 154.83 |
| 52 Week Low | $1.38 | $2.15 |
| 52 Week High | $6.56 | $8.00 |
| Indicator | IHRT | RLMD |
|---|---|---|
| Relative Strength Index (RSI) | 41.82 | 38.09 |
| Support Level | N/A | $3.13 |
| Resistance Level | $2.90 | $3.55 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | 0.03 | 0.04 |
| Stochastic Oscillator | 66.67 | 32.28 |
iHeartMedia Inc is a United States-based audio media company. The company operates through the segments of the Multiplatform Group, the Digital Audio Group, and the Audio & Media Services Group. The company derives prime revenue from the Multiplatform Group segment which includes the company's Broadcast radio, Networks and Sponsorships, and Events businesses. The Digital Audio Group segment includes all of the company's digital businesses, including podcasting; and the Audio & Media Services Group includes Katz Media Group, a full-service media representation business, and RCS Sound Software, a provider of scheduling and broadcast software and services.
Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.